MicroRNA-21: A central regulator of fibrotic diseases via various targets

Current Pharmaceutical Design

Volumn 21, Issue 17, 2015, Pages 2236-2242

  Huang, Ying ^a   He, Yong ^a   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Fobrotic disease; MicroRNA 21; Therapeutic target

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; GELATINASE A; MICRORNA; MICRORNA 1; MICRORNA 155; MICRORNA 208; MICRORNA 21; MICRORNA 29; MICRORNA 29B; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE B; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; SPROUTY HOMOLOGUE 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; MIRN21 MICRORNA, HUMAN; MIRN21 MICRORNA, MOUSE;

ARTICLE; ATRIAL FIBRILLATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HEART FIBROBLAST; HEART MUSCLE FIBROSIS; HUMAN; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; FIBROSIS; GENETICS; METABOLISM; MOUSE; PROGNOSIS;

ANIMALS; FIBROSIS; HUMANS; MICE; MICRORNAS; PROGNOSIS;

EID: 84929468150     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141226095701     Document Type: Article

References (80)

1. Malizia AP, Wang DZ. MicroRNAs in cardiomyocyte development. Wiley Interdiscip Rev Syst Biol Med 2011; 3: 183-90.
2. Berezikov E, Guryev V, van de Belt J, et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120: 21-4.
3. Salmanidis M, Pillman K, Goodall G, et al. Direct transcriptional regulation by nuclear microRNAs. Int J Biochem Cell Biol 2014.
4. Zhang W, Kong G, Zhang J, et al. MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1. PLoS One 2012; 7: e31450.
5. Pan Z, Sun X, Shan H, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 2012; 126: 840-50.
6. Xu W, Wang Z, Liu Y. The Characterization of microRNAMediated Gene Regulation as Impacted by Both Target Site Location and Seed Match Type. PLoS One 2014; 9: e108260.
7. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 460-71.
8. Ivashchenko A, Berillo O, Pyrkova A, et al. Binding Sites of miR-1273 Family on the mRNA of Target Genes. Biomed Res Int 2014; 2014: 620530.
9. Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 2009; 37: 918-25.
10. Thorland EC, Myers SL, Gostout BS, et al. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 2003; 22: 1225-37.
11. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-60.
12. Grishok A, Pasquinelli AE, Conte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 2001; 106: 23-34.
13. Gregory RI, Chendrimada TP, Cooch N, et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005; 123: 631-40.
14. Choy MK, Movassagh M, Siggens L, et al. High-throughput sequencing identifies STAT3 as the DNA-associated factor for p53-NF-kappaB-complex-dependent gene expression in human heart failure. Genome Med 2010; 2: 37.
15. Du J, Yang S, An D, et al. BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1. Cell Res 2009; 19: 487-96.
16. Fujita S, Ito T, Mizutani T, et al. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol 2008; 378: 492-504.
17. Loffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007; 110: 1330-3.
18. Velu CS, Baktula AM, Grimes HL. Gfi1 regulates miR-21 and miR-196b to control myelopoiesis. Blood 2009; 113: 4720-8.
19. Wickramasinghe NS, Manavalan TT, Dougherty SM, et al. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res 2009; 37: 2584-95.
20. Davis BN, Hilyard AC, Lagna G, et al. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454: 56-61.
21. Sahni V, Mukhopadhyay A, Tysseling V, et al. BMPR1a and BMPR1b signaling exert opposing effects on gliosis after spinal cord injury. J Neurosci 2010; 30: 1839-55.
22. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-9.
23. Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011; 124: 1537-47.
24. Lin J, Teo S, Lam DH, et al. MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme. Cell Death Dis 2012; 3: e398.
25. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-9.
26. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-803.
27. Connolly E, Melegari M, Landgraf P, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008; 173: 856-64.
28. Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170: 1831-40.
29. Ando Y, Yang GX, Kenny TP, et al. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse. J Autoimmun 2013; 41: 111-9.
30. Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation. Biochim Biophys Acta 2013; 1832: 876-83.
31. Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 2013; 304: C216-25.
32. Hemmann S, Graf J, Roderfeld M, et al. Expression of MMPs and TIMPs in liver fibrosis-a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007; 46: 955-75.
33. Pei Z, Meng R, Li G, et al. Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs. Toxicol Lett 2010; 199: 173-81.
34. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-beta signaling in fibrosis. Growth Factors 2011; 29: 196-202.
35. Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich) 2007; 9: 546-50.
36. van Rooij E, Olson EN. Searching for miR-acles in cardiac fibrosis. Circ Res 2009; 104: 138-40.
37. van Rooij E, Sutherland LB, Qi X, et al. Control of stressdependent cardiac growth and gene expression by a microRNA. Science 2007; 316: 575-9.
38. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105: 13027-32.
39. Dong S, Ma W, Hao B, et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol 2014; 7: 565-74.
40. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-4.
41. Cardin S, Guasch E, Luo X, et al. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol 2012; 5: 1027-35.
42. Akahori H, Tsujino T, Naito Y, et al. Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats. J Hypertens 2014; 32: 1534-41
43. Adam O, Lohfelm B, Thum T, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 2012; 107: 278.
44. Oudit GY, Sun H, Kerfant BG, et al. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004; 37: 449-71.
45. Roy S, Khanna S, Hussain SR, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009; 82: 21-9.
46. Bao H, Hu S, Zhang C, et al. Inhibition of miRNA-21 prevents fibrogenic activation in podocytes and tubular cells in IgA nephropathy. Biochem Biophys Res Commun 2014; 444: 455-60.
47. Wei J, Feng L, Li Z, et al. MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed Pharmacother 2013; 67: 387-92.
48. de Haas HJ, Arbustini E, Fuster V, et al. Molecular imaging of the cardiac extracellular matrix. Circ Res 2014; 114: 903-15.
49. Liang H, Zhang C, Ban T, et al. A novel reciprocal loop between microRNA-21 and TGFbetaRIII is involved in cardiac fibrosis. Int J Biochem Cell Biol 2012; 44: 2152-60.
50. Siddesha JM, Valente AJ, Yoshida T, et al. Docosahexaenoic acid reverses angiotensin II-induced RECK suppression and cardiac fibroblast migration. Cell Signal 2014; 26: 933-41.
51. Patrick DM, Montgomery RL, Qi X, et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010; 120: 3912-6.
52. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-8.
53. van Empel VP, De Windt LJ, da Costa Martins PA. Circulating miRNAs: reflecting or affecting cardiovascular disease? Curr Hypertens Rep 2012; 14: 498-509.
54. Zile MR, Mehurg SM, Arroyo JE, et al. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet 2011; 4: 614-9.
55. Villar AV, Garcia R, Merino D, et al. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int J Cardiol 2013; 167: 2875-81.
56. Friedman SL. Liver fibrosis: from mechanisms to treatment. Gastroenterol Clin Biol 2007; 31: 812-4.
57. Pellicoro A, Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Fibrogenesis Tissue Repair 2012; 5: S26.
58. Rao HY, Wei L, Li J, et al. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response. Hepatogastroenterology 2009; 56: 328-34.
59. Marquez RT, Bandyopadhyay S, Wendlandt EB, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010; 90: 1727-36.
60. Karakatsanis A, Papaconstantinou I, Gazouli M, et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013; 52: 297-303.
61. Zhang Z, Gao Z, Hu W, et al. 3,3'-Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR-21 expression. Br J Pharmacol 2013; 170: 649-60.
62. Frankel LB, Christoffersen NR, Jacobsen A, et al. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008; 283: 1026-33.
63. Wang Q, Sun Z, Yang HS. Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells. Oncogene 2008; 27: 1527-35.
64. Zhang Z, Zha Y, Hu W, et al. The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J Biol Chem 2013; 288: 37082-93.
65. Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012; 21: 355-61.
66. Noble PW, Homer RJ. Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2005; 33: 113-20.
67. Honeyman L, Bazett M, Tomko TG, et al. MicroRNA profiling implicates the insulin-like growth factor pathway in bleomycininduced pulmonary fibrosis in mice. Fibrogenesis Tissue Repair 2013; 6: 16.
68. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207: 1589-97.
69. Li P, Zhao GQ, Chen TF, et al. Serum miR-21 and miR-155 expression in idiopathic pulmonary fibrosis. J Asthma 2013; 50: 960-4.
70. Chung AC, Yu X, Lan HY. MicroRNA and nephropathy: emerging concepts. Int J Nephrol Renovasc Dis 2013; 6: 169-79.
71. Zhong X, Chung AC, Chen HY, et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013; 56: 663-74.
72. Zhong X, Chung AC, Chen HY, et al. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011; 22: 1668-81.
73. Eddy AA. The TGF-beta route to renal fibrosis is not linear: the miR-21 viaduct. J Am Soc Nephrol 2011; 22: 1573-5.
74. Okazaki Y, Yamasaki Y, Uchida HA, et al. Enhanced TGFbeta/ Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor. Clin Exp Nephrol 2007; 11: 77-87.
75. Wang JY, Gao YB, Zhang N, et al. Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-tomesenchymal transition in diabetic nephropathy. Am J Physiol Renal Physiol 2014; 306: F486-95.
76. Chung AC, Dong Y, Yang W, et al. Smad7 suppresses renal fibrosis via altering expression of TGF-beta/Smad3-regulated microRNAs. Mol Ther 2013; 21: 388-98.
77. Wang J, Gao Y, Ma M, et al. Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochem Biophys 2013; 67: 537-46.
78. Glowacki F, Savary G, Gnemmi V, et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One 2013; 8: e58014.
79. Cheng Y, Liu X, Zhang S, et al. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 2009; 47: 5-14.
80. Sayed D, Rane S, Lypowy J, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008; 19: 3272-82.